Genmab Stock Rallies on Stellar Cancer-Drug Data, Adding $10 Billion in a Week

Summary

Danish biotech Genmab A/S had a breakout week, and its stock gained about $10 billion in value on the back of stellar cancer-drug data. This summary rests on a single Bloomberg article, which gives only a headline-level account of the week and does not detail the trial results.

Timeline

1. Bloomberg

   30 Oct 2026, 09:01 UTCSource ↗

   Reports that Genmab A/S had a breakout week, with its stock adding about $10 billion in value after stellar cancer-drug data.